<DOC>
	<DOCNO>NCT00580723</DOCNO>
	<brief_summary>The purpose open-label study determine tolerance efficacy twice-daily application PRK 124 ( Pyratine-6 ) ( 0.125 % ) moisturize lotion improve sign symptom mild moderate facial rosacea .</brief_summary>
	<brief_title>Effects PRK 124 Lotion Acne Rosacea</brief_title>
	<detailed_description>Cytokinins plant growth factor regulate plant growth differentiation . PRK 124 ( N-furfuryl-9- ( 2-tetrahydropyranyl ) adenine ) ( Pyratine 6™ ) cytokinin show modulatory , anti-ROS ( reactive oxygen specie ) , antisenescence effect growth human skin cell . Recent clinical study show PRK 124 ( 0.1 % ) treatment 40 subject 12 week improve appearance photodamaged facial skin decrease fine wrinkle , roughness mottle hyperpigmentation . Treatment PRK 124 lotion furthermore decrease skin transepidermal water loss also increase skin moisture content . The topical PRK 124 lotion well tolerated subject significant increase erythema irritation . Treatment PRK 124 show decrease acne erythema observe baseline . Rosacea common , chronic dermatosis characterize papule pustule , persistent erythema telangiectasia . The objective study compare long-term efficacy tolerance PRK 124 ( 0.125 % ) moisturize lotion apply twice daily 48 week improve clinical sign symptom inflammatory acne rosacea well cutaneous sign skin photodamage . Study Design : Twenty four volunteer mild-to-moderate facial rosacea participate single center , open-label study design evaluate subject=s tolerance effectiveness PRK 124 ( 0.125 % ) moisturize lotion apply twice daily 48 week , improve sign symptom acne rosacea . Subjects apply test lotion twice daily , morning evening bedtime . Subjects assess baseline 4 , 8 12 week treatment improvement clinical sign symptom acne rosacea effect treatment transepidermal water loss ( TEWL ) . In addition , subject 's tolerance assess follow-up visit ( week 4 , 8 , 12 ) . Facial photograph obtain baseline 4 , 8 12 week . Subjects give opportunity continue treatment 36 additional week . Subjects must normal clinical laboratory test , female , negative urine pregnancy test 12 week continue 36 week treatment . Clinical laboratory test urine pregnancy test repeat week 48 early study completion . Clinical assessment do week 24 , 36 48 last 36 week . Additional objective measure skin moisture content skin erythema use chromameter do week 12 follow-up visit ( week 24 , 36 48 ) . Telephone follow-up do week 16 , 20 , 28 , 32 40 ass subject tolerance compliance . Primary Study Variables : The primary study variable : Observations Investigator : - Inflammatory lesion count - Erythema telangiectasia severity - Global assessment severity - Overall improvement baseline - Photodamage ( fine wrinkle , texture , mottle hyperpigmentation ) - Transepidermal water loss ( TEWL ) - Skin moisture content - Skin erythema measure chromameter Subject self assessment : - Signs &amp; symptom ( burning/stinging , erythema/telangiectasia , papules/pustules ) - Overall improvement baseline - Photodamage ( fine wrinkle , texture , mottle hyperpigmentation ) - Cosmetic acceptability The local skin tolerance treatment assess Investigator subject .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<criteria>least 21 year old reasonably good health define study doctor routine laboratory test evaluate blood cell count , kidney liver function female childbearing age , pregnant nursing negative urine pregnancy test ( except surgically sterile least 1 year menopausal ) female , agree use medically acceptable form birth control throughout entire study ( medically acceptable form birth control include oral contraceptive [ `` pill '' ] , implant Norplant® , injectable progesterone [ Depoprovera® ] , diaphragm spermicide condom spermicide ) must mild moderate acne rosacea willing refrain use nonapproved lotion , moisturizer , cleanser lotion affect facial area treatment period capable understanding give write , voluntary inform consent study screen willing consent facial photograph baseline followup visit monitor treatment test product . history evidence chronic reoccurring skin disease disorder ( e.g. , psoriasis , eczema , etc . ) affect face know suspected hypersensitivity study treatment ingredient use systemic retinoids within 6 month prior study entry ( e.g. , acitretin , isotretinoin ) receive treatment systemic corticosteroid ( e.g . prednisone ) antibiotic within 1 month use topical treatment face retinoids ( e.g . tretinoin , adapalene ) , antibiotic corticosteroid , within 2 week prior study entry unwilling use sunscreen SPF 30 study participate clinical trial involve investigational drug cosmetic product procedure within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>acne</keyword>
	<keyword>rosacea</keyword>
	<keyword>acne rosacea</keyword>
	<keyword>papulopustular rosacea</keyword>
	<keyword>erythema</keyword>
	<keyword>telangiectasia</keyword>
	<keyword>flush</keyword>
</DOC>